Testing Small-Quantity Lipid-Based Nutritional Supplements to Improve Vaccination and Child Health in Rural Chad and Niger
Led by Alliance for International Medical Action · Updated on 2026-05-18
20000
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Malnutrition and infectious diseases create a harmful cycle that severely affects children in low- and middle-income countries, increasing their risk of death and developmental problems. This study focuses on rural areas of Chad and Niger, where malnutrition rates are high and vaccination coverage is low. Researchers are evaluating whether giving children small-quantity lipid-based nutritional supplements SQ-LNS alongside routine immunization improves vaccination rates and child health in these vulnerable populations.
The study compares two groups one receiving the standard Expanded Program on Immunization EPI alone, and the other receiving EPI combined with daily SQ-LNS supplementation for children aged 6 to 18 months. SQ-LNS are nutrient-rich, ready-to-use supplements given as a 20-gram sachet per day to support child growth and development. The program runs for 12 months, with SQ-LNS distributed through health centers and community health huts, integrated with existing vaccination services.
Participants will be assessed through annual household surveys measuring vaccination coverage, nutritional status using mid-upper arm circumference MUAC, and treatment outcomes for malnourished children. Additional qualitative research will explore barriers and facilitators to vaccination and supplementation, including gender influences. Researchers will also use modeling and economic analyses to estimate the health impact and cost-effectiveness of the combined program, with follow-up planned for up to one year after starting supplementation.
CONDITIONS
Brief Title
OptiMAx Will Test Whether SQ-LNS Incentivises Vaccination Uptake in Rural Chad and Niger, With a Cost Effectiveness Analysis. It Will Also Look at Whether Having Received SQ-LNS Before Becoming Malnourished Leads to Better Outcomes for Children Treated Under the OptiMA Protocol.
Research Team
K
Kevin Phelan, MSc
S
Susan Shepherd, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Children aged 6 to 12 months who are not malnourished are eligible for SQ-LNS supplementation until 18 months of age.
Children aged 6 to 59 months will be surveyed for nutritional status; vaccination analysis focuses on children aged 12 to 23 months.
Parents or legal guardians must provide informed oral consent.
Participants must reside in the neighborhoods included in the study.
Personnel involved in the OptiMAx intervention and community members may participate in qualitative studies.
Mothers of children benefiting from the intervention, their male partners or spouses, non-adherents, and community members will be recruited for interviews and focus groups.
You will not qualify if you...
Children eligible by age with MUAC less than 125 mm or edema will first receive treatment for acute malnutrition before resuming SQ-LNS supplementation.
Parents or guardians under 15 years of age are excluded from the mixed-methods process evaluation.
There are no exclusion criteria for the annual household surveys.
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
SQ-LNS Supplementation and Vaccination
Duration - Up to 12 months until participants reach 18 months of age
Participants aged 6 to 12 months receive daily small quantity lipid-based nutritional supplements (SQ-LNS) combined with routine Expanded Programme on Immunization (EPI) services at health centers or huts. This stage aims to increase vaccination coverage and improve nutritional status through monthly supplement distribution integrated with immunization visits.
Monthly visits for supplement distribution and vaccination
Follow-up and Assessment
Duration - Assessment at approximately 1 year after beginning SQ-LNS supplementation
After supplementation ends, participants aged 12 to 23 months are assessed for vaccination coverage, nutritional status, and treatment outcomes for acute malnutrition to evaluate the impact of the intervention.
1 visit (in-person) for endline vaccination coverage survey and nutritional assessment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Similar Trials
Phase II Study of Adjuvant Dendritic Cell Vaccination Using Patients Own Tumor Material After Surgery for Stage IV Rare Cancers including Head and Neck, Neuroendocrine Tumors, and Soft Tissue Sarcoma
Study on Remote Eye Tracking to Understand Vaccine Promotion Messages in Rural New England Adults
Using Tailored Personal Stories and Informational Videos to Encourage Vaccination Among Adults 50 and Older
Effectiveness of a COVID-19 Booster Vaccine to Prevent Re-infection and Study of Antibody Changes in Lung Cancer Patients Receiving Systemic Anti-cancer Treatment
Study on Dengue Virus Infection Rates and Vaccine Acceptance in Children Aged 9 to 17 in Martinique and Guadeloupe
Evaluating Immune Responses and Safety of the RSVPreF3 Vaccine in Lung Transplant Recipients and Older Adults
Study on Immune Responses to Meningococcal B Vaccine in Healthy Adults Aged 18 to 50
Including Transgender and Cisgender Men and Women
Evaluating Nutritional Health and Muscle Loss to Predict Risks After Lung Cancer Surgery in Adults
A Prospective Study Using Imaging and Clinical Assessments
Study of How Blood and Nasal Antibodies Fight COVID-19 and Monkeypox Over Time After Vaccination or Treatment
Testing Small-Quantity Lipid-Based Nutritional Supplements to Improve Vaccination and Child Health in Rural Chad and Niger
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Simplifying and optimising the management of uncomplicated acute malnutrition in children aged 6-59 months in the Democratic Republic of the Congo (OptiMA-DRC): a non-inferiority, randomised controlled trial.
Factors associated with non-response and nutritional status of non-responders at 6-month post-discharge: a cohort study nested in a MUAC-based nutrition programme for acutely malnourished children in Mirriah, Niger.
Small-quantity lipid-based nutrient supplements for children age 6-24 months: a systematic review and individual participant data meta-analysis of effects on developmental outcomes and effect modifiers.
Elizabeth L Prado, Charles D Arnold, K Ryan Wessells...
Treatment outcomes and associated factors for hospitalization of children treated for acute malnutrition under the OptiMA simplified protocol: a prospective observational cohort in rural Niger.
Optimising the dosage of ready-to-use therapeutic food in children with uncomplicated severe acute malnutrition in the Democratic Republic of the Congo: a non-inferiority, randomised controlled trial.
New approach to simplifying and optimising acute malnutrition treatment in children aged 6-59 months: the OptiMA single-arm proof-of-concept trial in Burkina Faso.